|
1
|
Maron BJ: Hypertrophic cardiomyopathy: A
systematic review. JAMA. 287:1308–1320. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Chugh SS, Reinier K, Teodorescu C, Evanado
A, Kehr E, Al Samara M, Mariani R, Gunson K and Jui J: Epidemiology
of sudden cardiac death: Clinical and research implications. Prog
Cardiovasc Dis. 51:213–228. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Beohar N, Zajarias A, Thourani VH,
Herrmann HC, Mack M, Kapadia S, Green P, Arnold SV, Cohen DJ,
Généreux P, et al: Analysis of early out-of hospital mortality
after transcatheter aortic valve implantation among patients with
aortic stenosis successfully discharged from the hospital and alive
at 30 days (from the placement of aortic transcatheter valves
trial). Am J Cardiol. 114:1550–1555. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Tham YK, Bernardo BC, Ooi JY, Weeks KL and
McMullen JR: Pathophysiology of cardiac hypertrophy and heart
failure: Signaling pathways and novel therapeutic targets. Arch
Toxicol. 89:1401–1438. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Jeong K, Kwon H, Min C and Pak Y:
Modulation of the caveolin-3 localization to caveolae and STAT3 to
mitochondria by catecholamine-induced cardiac hypertrophy in H9c2
cardiomyoblasts. Exp Mol Med. 41:226–235. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Lee H, Yoo YS, Lee D and Song EJ:
Cholesterol induces cardiac hypertrophy by activating the AKT
pathway. J Steroid Biochem Mol Biol. 138:307–313. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Steppan CM, Bailey ST, Bhat S, Brown EJ,
Banerjee RR, Wright CM, Patel HR, Ahima RS and Lazar MA: The
hormone resistin links obesity to diabetes. Nature. 409:307–312.
2001. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Kim M, Oh JK, Sakata S, Liang I, Park W,
Hajjar RJ and Lebeche D: Role of resistin in cardiac contractility
and hypertrophy. J Mol Cell Cardiol. 45:270–280. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Muse ED, Obici S, Bhanot S, Monia BP,
McKay RA, Rajala MW, Scherer PE and Rossetti L: Role of resistin in
diet-induced hepatic insulin resistance. J Clin Invest.
114:232–239. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Graveleau C, Zaha VG, Mohajer A, Banerjee
RR, Dudley-Rucker N, Steppan CM, Rajala MW, Scherer PE, Ahima RS,
Lazar MA, et al: Mouse and human resistins impair glucose transport
in primary mouse cardiomyocytes, and oligomerization is required
for this biological action. J Biol Chem. 280:31679–31685. 2005.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Chen YH, Hung PF and Kao YH: IGF-I
downregulates resistin gene expression and protein secretion. Am J
Physiol Endocrinol Metab. 288:E1019–E1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Patel L, Buckels AC, Kinghorn IJ, Murdock
PR, Holbrook JD, Plumpton C, Macphee CH and Smith SA: Resistin is
expressed in human macrophages and directly regulated by PPAR gamma
activators. Biochem Biophys Res Commun. 300:472–476. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Steppan CM and Lazar MA: The current
biology of resistin. J Intern Med. 255:439–447. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Pang SS and Le YY: Role of resistin in
inflammation and inflammation-related diseases. Cell Mol Immunol.
3:29–34. 2006.PubMed/NCBI
|
|
15
|
Bokarewa M, Nagaev I, Dahlberg L, Smith U
and Tarkowski A: Resistin, an adipokine with potent proinflammatory
properties. J Immunol. 174:5789–5795. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kunnari AM, Savolainen ER, Ukkola OH,
Kesäniemi YA and Jokela MA: The expression of human resistin in
different leucocyte lineages is modulated by LPS and TNFalpha.
Regul Pept. 157:57–63. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Schwartz DR and Lazar MA: Human resistin:
Found in translation from mouse to man. Trends Endocrinol Metab.
22:259–265. 2011.PubMed/NCBI
|
|
18
|
Szokodi I, Tavi P, Földes G,
Voutilainen-Myllylä S, Ilves M, Tokola H, Pikkarainen S, Piuhola J,
Rysä J, Tóth M, et al: Apelin, the novel endogenous ligand of the
orphan receptor APJ, regulates cardiac contractility. Circ Res.
91:434–440. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Kuba K, Zhang L, Imai Y, Arab S, Chen M,
Maekawa Y, Leschnik M, Leibbrandt A, Markovic M, Schwaighofer J, et
al: Impaired heart contractility in Apelin gene-deficient mice
associated with aging and pressure overload. Circ Res. 101:e32–e42.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Maguire JJ, Kleinz MJ, Pitkin SL and
Davenport AP: [Pyr1]apelin-13 identified as the predominant apelin
isoform in the human heart: Vasoactive mechanisms and inotropic
action in disease. Hypertension. 54:598–604. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Wang W, McKinnie SM, Patel VB, Haddad G,
Wang Z, Zhabyeyev P, Das SK, Basu R, McLean B, Kandalam V, et al:
Loss of Apelin exacerbates myocardial infarction adverse remodeling
and ischemia-reperfusion injury: Therapeutic potential of synthetic
Apelin analogues. J Am Heart Assoc. 2:e0002492013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Li L, Zeng H and Chen JX: Apelin-13
increases myocardial progenitor cells and improves repair
postmyocardial infarction. Am J Physiol Heart Circ Physiol.
303:H605–H618. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ceylan-Isik AF, Kandadi MR, Xu X, Hua Y,
Chicco AJ, Ren J and Nair S: Apelin administration ameliorates high
fat diet-induced cardiac hypertrophy and contractile dysfunction. J
Mol Cell Cardiol. 63:4–13. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Liu P, Cheng GC, Ye QH, Deng YZ and Wu L:
LKB1/AMPK pathway mediates resistin-induced cardiomyocyte
hypertrophy in H9c2 embryonic rat cardiomyocytes. Biomed Rep.
4:387–391. 2016.PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2(−Delta Delta C(T)) Method. Methods. 25:402–408. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Banerjee RR, Rangwala SM, Shapiro JS, Rich
AS, Rhoades B, Qi Y, Wang J, Rajala MW, Pocai A, Scherer PE, et al:
Regulation of fasted blood glucose by resistin. Science.
303:1195–1198. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Rajala MW, Obici S, Scherer PE and
Rossetti L: Adipose-derived resistin and gut-derived resistin-like
molecule-beta selectively impair insulin action on glucose
production. J Clin Invest. 111:225–230. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Gao J, Chua C Chang, Chen Z, Wang H, Xu X,
C Hamdy R, McMullen JR, Shioi T, Izumo S and Chua BH: Resistin,
anadipocytokine, offers protection against acute myocardial
infarction. J Mol Cell Cardiol. 43:601–609. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Gualillo O, González-Juanatey JR and Lago
F: The emerging role of adipokines as mediators of cardiovascular
function: Physiologic and clinical perspectives. Trends Cardiovasc
Med. 17:275–283. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Rothwell SE, Richards AM and Pemberton CJ:
Resistin worsens cardiac ischaemia-reperfusion injury. Biochem
Biophys Res Commun. 349:400–407. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Bobbert P, Jenke A, Bobbert T, Kühl U,
Rauch U, Lassner D, Scheibenbogen C, Poller W, Schultheiss HP and
Skurk C: High leptin and resistin expression in chronic heart
failure: Adverse outcome in patients with dilated and inflammatory
cardiomyopathy. Eur J Heart Fail. 14:1265–1275. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Chemaly ER, Hadri L, Zhang S, Kim M,
Kohlbrenner E, Sheng J, Liang L, Chen J, K-Raman P, Hajjar RJ, et
al: Long-term in vivo resistin overexpression induces myocardial
dysfunction and remodeling in rats. J Mol Cell Cardiol. 51:144–155.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Kang S, Chemaly ER, Hajjar RJ and Lebeche
D: Resistin promotes cardiac hypertrophy via the AMP-activated
protein kinase/mammalian target of rapamycin (AMPK/mTOR) and c-Jun
N-terminal kinase/insulin receptor substrate 1 (JNK/IRS1) pathways.
J Biol Chem. 286:18465–18473. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kageyama K, Hanada K and Suda T:
Regulation of corticotropin-releasing factor receptor type 2beta
mRNA by mitogen-activated protein kinases in aortic smooth muscle
cells. Regul Pept. 126:223–231. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Iwanaga Y, Kihara Y, Takenaka H and Kita
T: Down-regulation of cardiac apelin system in hypertrophied and
failing hearts: Possible role of angiotensin II-angiotensin type 1
receptor system. J Mol Cell Cardiol. 41:798–806. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Földes G, Horkay F, Szokodi I, Vuolteenaho
O, Ilves M, Lindstedt KA, Mäyränpää M, Sármán B, Seres L, Skoumal
R, et al: Circulating and cardiac levels of apelin, the novel
ligand of the orphan receptor APJ, in patients with heart failure.
Biochem Biophys Res Commun. 308:480–485. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Pchejetski D, Foussal C, Alfarano C,
Lairez O, Calise D, Guilbeau-Frugier C, Schaak S, Seguelas MH,
Wanecq E, Valet P, et al: Apelin prevents cardiac fibroblast
activation and collagen production through inhibition of
sphingosine kinase 1. Eur Heart J. 33:2360–2369. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Zeng H, He X, Hou X, Li L and Chen JX:
Apelin gene therapy increases myocardial vascular density and
ameliorates diabetic cardiomyopathy via upregulation of sirtuin 3.
Am J Physiol Heart Circ Physiol. 306:H585–H597. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Jia YX, Pan CS, Zhang J, Geng B, Zhao J,
Gerns H, Yang J, Chang JK, Tang CS and Qi YF: Apelin protects
myocardial injury induced by isoproterenol in rats. Regul Pept.
133:147–154. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Siddiquee K, Hampton J, Khan S, Zadory D,
Gleaves L, Vaughan DE and Smith LH: Apelin protects against
angiotensin II-induced cardiovascular fibrosis and decreases
plasminogen activator inhibitor type-1 production. J Hypertens.
29:724–731. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Scimia MC, Hurtado C, Ray S, Metzler S,
Wei K, Wang J, Woods CE, Purcell NH, Catalucci D, Akasaka T, et al:
APJ acts as a dual receptor in cardiac hypertrophy. Nature.
488:394–398. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Charo DN, Ho M, Fajardo G, Kawana M, Kundu
RK, Sheikh AY, Finsterbach TP, Leeper NJ, Ernst KV, Chen MM, et al:
Endogenous regulation of cardiovascular function by apelin-APJ. Am
J Physiol Heart Circ Physiol. 297:H1904–H1913. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Mutlak M and Kehat I: Extracellular
signal-regulated kinases 1/2 as regulators of cardiac hypertrophy.
Front Pharmacol. 6:1492015. View Article : Google Scholar : PubMed/NCBI
|
